Company / Operating Income per Share
Jade Biosciences, Inc. Operating Income per Share History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$2.61
FY2024
5-year range
-$36.70 / -$1.87
FY2020-FY2024
Trend
+15.6%
vs FY2023
Sector context
#133 of 196
Health Care
What the data says
At $-2.61, Jade Biosciences, Inc.'s operating income per share ranks #133 of 196 in the Health Care sector. Operating Income per Share returned to growth in FY2024 after 2 years of decline, reaching $-2.61.
Based on SEC 10-K filings.
-2.61 in FY2024.
Declined from $-2.18 to $-2.61 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#133 of 196 in Health CareTop 68% of 196This company -$2.61 Sector average -$46.00
▼
+94.3% above sector average
Key checks
Key Insights
- In FY2024, operating income per share increased 15.6% year-over-year.
- Ranks #133 out of 196 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2021.
- Lowest operating income per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.61 | +15.6% |
| FY2023 | -$3.09 | -42.1% |
| FY2022 | -$2.18 | -16.2% |
| FY2021 | -$1.87 | +94.9% |
| FY2020 | -$36.70 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026